Core Viewpoint - NKGen Biotech's Troculeucel shows promise in treating Alzheimer's disease by enhancing neuroinflammation modulation and improving cognitive function in patients, as evidenced by clinical trial data presented at AAIC 2025 [1][9]. Company Overview - NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing innovative autologous and allogeneic natural killer (NK) cell therapeutics [12]. - The company is headquartered in Santa Ana, California, and is advancing Troculeucel for neurodegenerative disorders and various cancers [13]. Product Details - Troculeucel is a first-in-kind, autologous, non-genetically modified NK cell product with over 90% activating receptor expression and significantly increased cytotoxicity [2]. - The product has shown the ability to internalize and degrade amyloid and α-synuclein aggregates in vitro, indicating its potential effectiveness in Alzheimer's disease [5]. Clinical Trial Findings - In Phase 1 studies, 92% of patients (12 out of 13) exhibited stable or improved Alzheimer's Disease Composite Score (ADCOMS) after three months of treatment [7][14]. - Notably, two patients with moderate Alzheimer's improved to mild-stage after receiving the highest dose of Troculeucel [7]. - Biomarker data indicated that 60%, 90%, and 70% of patients showed stabilization or improvement in CSF levels of Aβ42/40, p-Tau181, and α-synuclein, respectively, after three months [5]. Mechanism of Action - Troculeucel demonstrates high expression of receptors involved in modulating neuroinflammation, including 91.25% CXCR3 expression, which facilitates migration towards the CSF in Alzheimer's patients [3][10]. - The therapy selectively targets autoreactive T cells while sparing resting T cells, potentially reducing neuroinflammation [4][9]. Additional Observations - Six out of ten patients showed decreased levels of Glial Fibrillary Acid Protein (GFAP) after three months, indicating a reduction in neuroinflammation [6]. - The findings suggest that Troculeucel may have broader applications for other neurodegenerative diseases beyond Alzheimer's [9].

Core Viewpoint - NKGen Biotech, Inc. is advancing its innovative NK cell therapeutics, particularly focusing on the presentation of preliminary results for its troculeucel therapy in treating moderate Alzheimer's disease at the upcoming AD/PD™ 2025 conference [1][3]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, specializing in the development and commercialization of autologous and allogeneic NK cell therapeutics [6]. - The company is developing troculeucel, a novel patient-specific NK cell immunotherapeutic drug candidate, for neurodegenerative disorders and various cancers [5]. Conference Participation - Paul Y. Song, M.D., the CEO of NKGen, will present at the AD/PD™ 2025 conference, which is a significant event for discussing advancements in Alzheimer's and Parkinson's research [1][2]. - The conference is expected to attract over 4,700 participants from more than 70 countries, showcasing 2,250 abstracts in 2024 [2]. Presentation Details - The presentation titled "Preliminary Cognitive Improvement in Phase 1 Cohort of Moderate Alzheimer's Disease Subjects Treated with Autologous Natural Killer Cells (Troculeucel; SNK01)" will take place on April 5, 2025, focusing on three-month cognitive and biomarker results from the Phase 1 cohort of the clinical trial [3]. - New data from the six-month analysis of this cohort will also be discussed during the presentation [3]. Product Information - Troculeucel, also known as SNK01, has received the International Nonproprietary Name (INN) approval from the World Health Organization (WHO), marking a significant milestone for NKGen in bringing this therapy to market [5].